NDATOPICALSOLUTION
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
KERYDIN (tavaborole) by R-Pharm US is protein synthesis inhibitors [moa]. First approved in 2014.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KERYDIN (tavaborole) is a topical antifungal solution approved in 2014 for onychomycosis (fungal nail infection). It works by inhibiting fungal protein synthesis, offering a non-systemic alternative to oral antifungals. The product targets patients seeking topical-only therapy to avoid systemic drug interactions and hepatotoxicity concerns.
$0.019BPart D
PeakStable
Mature topical dermatology asset with modest Medicare utilization; small commercial footprint suggests selective sales model and lean team structure.
Mechanism of Action
Protein Synthesis Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents
Started Oct 2015
55 enrolled
OnychomycosisTinea Unguium
Career Relevance
Working on KERYDIN offers exposure to mature specialty dermatology commercialization in a niche indication with modest headcount. Career progression may be limited by modest growth trajectory; best suited for professionals seeking stable, focused product expertise rather than high-growth launch experience.
Brand Manager
Worked on KERYDIN at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.